Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer
Stephanie Graff, Director of Breast Oncology at Brown University Health, shared a post on LinkedIn about recent article published in Targeted Oncology:
“Congratulations to all my colleagues and collaborators who have worked on Datopotumab deruxtecan. Excited to have another therapeutic option to treat advanced HR+ breast cancer.”
“FDA Approves Dato-DXd in HR+/HER2– Breast Cancer”
Stephanie Graff is the Director of Breast Oncology at Brown University Health and an Associate Professor of Medicine at Brown University’s Legorreta Cancer Center.
She also serves as the Director of Breast Oncology at Lifespan and is a Medical Advisor for the Dr. Susan Love Foundation for Breast Cancer Research.She is an Associate Editor of Cancer Medicine, and chairs the editorial board of Oncology Times.
More posts featuring Stephanie Graff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023